CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Pfizer
Amgen
Pfizer
Amgen
BioNTech SE
Lyell Immunopharma, Inc.
BeOne Medicines
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Immatics US, Inc.
Genmab
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Pfizer
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Beijing Biotech
Gilead Sciences
AVEO Pharmaceuticals, Inc.
Otsuka Pharmaceutical Co., Ltd.
Autolus Limited
Genmab
Hangzhou Sumgen Biotech Co., Ltd.
Alpha Tau Medical LTD.
Bristol-Myers Squibb
SecuraBio
ModernaTX, Inc.
Hoffmann-La Roche
ModernaTX, Inc.
AstraZeneca
IDEAYA Biosciences
Nanjing IASO Biotechnology Co., Ltd.
Novartis
Genentech, Inc.
Daehwa Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals
Daiichi Sankyo
Incyte Corporation
Bristol-Myers Squibb
Telix Pharmaceuticals (Innovations) Pty Limited
Keystone Nano, Inc
Takeda
Hoffmann-La Roche
Prescient Therapeutics, Ltd.
Debiopharm International SA
Servier
Amgen